Andere Sprachen OmniAb, Inc.

Aktien

A3DZDL

US68218J1034

OABI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 21.06.2024			% 5 Tage	% 1. Jan.
3,99 ^USD	-1,72 %		-5,45 %	-35,33 %

29.05.	Omniab-Insider kaufte Aktien im Wert von $1,059,840, laut einer aktuellen SEC-Einreichung	MT
09.05.	OmniAb, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

OmniAb : Submission of Matters to a Vote of Security Holders Form 8 K	21.06.
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology	03.06.
Omniab Insider Bought Shares Worth $1,059,840, According to a Recent SEC Filing	29.05.
OmniAb to Participate in the Jefferies Global Healthcare Conference	20.05.
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit	15.05.
OmniAb : May 2024 Corporate Overview	10.05.
Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M	09.05.
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights	09.05.
OmniAb to Participate in Five Investor Conferences in May	01.05.
OmniAb to Report First Quarter 2024 Financial Results on May 9	22.04.
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	16.04.
OmniAb : March 2024 Corporate Overview	26.03.
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing	25.03.
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	21.03.
OmniAb Swings to Q4 Loss, Revenue Declines	20.03.
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M	20.03.
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20.03.
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	20.03.
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen OmniAb, Inc.

Aktien

A3DZDL

US68218J1034

OABI

Andere Sprachen

Filter